Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.

OSAKA, Japan & CAMBRIDGE, Mass., December 27, 2024--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA ...

CHESTER, N.Y.--(BUSINESS WIRE)--Innovative Health Sciences, LLC (“IHS” or the “Company”) management announced today that IHS has received FDA clearance for its Insignis™ Subcutaneous Needle Sets. This ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and ...

Basel, 11 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced late-breaking data from the Phase III OCARINA II study. Study results demonstrate the effect of OCREVUS® (ocrelizumab) as an ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and ...

CHESTER, N.Y., June 1, 2011 /PRNewswire/ -- Repro-Med Systems, Inc., (REPR.PK) announced today that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

BOSTON, June 8, 2015 /PRNewswire/ -- BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant ...